Vifor Pharma Bolsters Its Presence In Vascular Calcification Field Via Two Acquisition Deals

  • Vifor Pharma GNHAY has acquired Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company that focuses on progressive vascular calcification disorders.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the shares of Sanifit Therapeutics. In return, it will receive all the global rights to SNF472 under development for patients with an end-stage renal disease with calcified uremic arteriolopathy and peripheral arterial disease (PAD).
  • Sanifit's shareholders will receive an initial payment of €205 million, additional milestone payments of up to €170 million.
  • Vifor also acquired Inositec AG, a Swiss company, developing non-dialysis treatments for soft tissue and vascular calcification disorders.
  • Inositec's asset INS-3001 is a once-daily subcutaneous treatment for patients with vascular calcification disorders PAD and Aortic Valve Stenosis (AVS).
  • Inositec will receive an upfront payment of CHF 20 million and be eligible for success-based clinical earn-out payments in the low triple-digit million range.
  • Price Action: GNHAY shares closed at $25.85.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!